Using regulatory T cells to treat neurodegenerative diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and efficacy of autologous human polyclonal regulatory T cell injections (NP001) in patients with neurodegenerative diseases such as ALS, Alzheimer's Disease, and Multiple System Atrophy. Participants will undergo apheresis to collect cells for the manufacturing of NP001, which will be administered intrathecally at specified doses over a 12-month period. The study is open-label and non-randomized, with follow-up assessments to monitor safety and efficacy outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\-

Patients must meet all of the following criteria to be eligible for enrollment in this study:

1. Male or female patients aged 18 to 70 years;
2. According to current international diagnostic criteria:

   ALS: defined by the Gold Coast Diagnostic Criteria (Shefner, 2020) as having a diagnosis of sporadic or familial amyotrophic lateral sclerosis (ALS), diagnosed as a probable, probable, or definite patient with laboratory support according to the World Federation of Neurology El Escorial criteria;
3. If there is a stable dose for more than one month prior to study entry. For example, patients with ALS can continue treatment with riluzole (Rilutek®) and/or edaravone (Radicava®);
4. Patients must have \> two weeks after the end of major surgery and after the completion of participation in other research trials;
5. Patients must have recovered from clinical toxicity (CTCAE \[5th Edition\] toxicity values have resolved to \< 2);
6. Serum creatinine less than or equal to 2.0 mg/dL;
7. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x upper limit of normal;
8. Bilirubin \< 1.5 (except Gilbert's disease);
9. Lung slow vital capacity (SVC) \> 70% of predicted normal;
10. No history of abnormal bleeding tendency;
11. Informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care.

Exclusion Criteria:

\-

Subjects with any of the following cannot be enrolled in this study:

1. uncontrolled infection;
2. \< 3 drugs do not adequately control hypertension;
3. Documented history of pulmonary embolism within 6 months of enrollment;
4. Clinically significant cardiology, defined as: myocardial infarction, NYHA-graded class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment;
5. Patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis;
6. Seropositive for HIV, hepatitis B or hepatitis C;
7. Pregnant or lactating patients;
8. Patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception;
9. Participation in any other interventional study;
10. Treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. Patient participation in observational/non-interventional clinical studies will be discussed with the Medical Monitor;
11. Prior treatment with ALS gene or cell therapy;
12. History of clinically significant tumor, liver or kidney disease, or other uncontrolled disease;
13. presence of a feeding tube;
14. Current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-Bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs;
15. Subjects who, in the opinion of the investigator, are at significant risk of suicide;
16. Other conditions that the investigator considers unsuitable for enrollment.

Where it's running

• The First Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Mingqi Lu, MD., PhD
• Email: lumingqi@novabiotx.com
• Phone: 609-716-7786; +86 15800843507

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of respiratory impairment in ALS using breathing, MRI, and blood markers

  This study tests whether breathing patterns, MRI changes in the brainstem and spinal cord, and blood markers can reveal early ALS signs, especially in people with genetic risk or early symptoms.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07844590

• Plasmapheresis for ALS with anti-NRIP autoantibody

  This study tests whether a few plasmapheresis sessions can help people with ALS who have anti-NRIP autoantibody by keeping the antibody levels low.

  Recruiting National Taiwan University Hospital · Taipei City, Taipei · NCT07726563

• Implanted brain interface to let people with severe paralysis control assistive devices

  It will try an implanted brain interface that records and stimulates brain signals so adults with severe paralysis can control assistive devices and receive sensory feedback.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07521930

• Do video recordings of multidisciplinary clinics help ALS patients and caregivers?

  This study tests whether providing a video recording of ALS multidisciplinary clinic visits, in addition to written notes, helps patients and their caregivers manage information and feel better about care.

  Recruiting Trustees of Dartmouth College · Scottsdale, Arizona and 6 other locations · NCT07454733

• Measuring Hsp90 levels in the human brain

  This trial tests whether a PET tracer called [11C]HSP990 can measure Hsp90 levels in the brains of healthy adults and people with Parkinson's disease, Alzheimer's disease, or ALS.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaam-Brabant · NCT07380204

• NB-4746 in people with ALS

  This trial tests NB-4746 against placebo to see if it is safe and may help people with ALS.

  Recruiting at 12 sites Phase 1/2 Nura Bio · Concord, New South Wales and 11 other locations · NCT07369076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.